neuroinflammation – Discover Pharma

Welcome to Discover Pharma! Today is : October 23, 2026

neuroinflammation

Central Nervous System,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development
BioVie reports Phase 2 Parkinson’s trial results for bezisterim
BioVie has reported topline results from a Phase 2 trial [...]

August 7, 2026
Central Nervous System,Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas
AC Immune advances Parkinson’s and Alzheimer’s pipeline with key clinical milestones ahead
AC Immune has outlined a series of clinical milestones expected [...]

August 5, 2026
Central Nervous System,Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas
ABLi reports biomarker changes supporting disease-modifying potential of Parkinson’s drug
ABLi Therapeutics has reported coordinated changes across 11 biomarkers linked [...]

August 4, 2026
Central Nervous System,Clinical & Regulatory,Drug Discovery & Development,Research & Development
Vandria reports Phase 1 data supporting Alzheimer’s development for VNA-318
New Phase 1 data show Vandria’s VNA-318 reaches the human [...]

July 13, 2026
Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas
AC Immune doses first participant in Phase 1 trial of NLRP3 inhibitor ACI-19764
AC Immune has initiated a Phase 1 trial of its [...]

May 5, 2026

main menu

recent posts

get connected

This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.

OK